11/14
11:13 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at BMO Capital Markets from $28.00 to $27.00. They now have an "outperform" rating on the stock.
Low
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at BMO Capital Markets from $28.00 to $27.00. They now have an "outperform" rating on the stock.
11/14
08:15 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Medium
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
11/13
07:00 am
acrv
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Medium
Report
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
10/17
08:00 am
acrv
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
Medium
Report
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
10/16
04:00 pm
acrv
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/11
08:00 am
acrv
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
Low
Report
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
9/16
10:09 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
Medium
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
9/16
09:13 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $28.00 price target on the stock, up previously from $25.00.
High
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $28.00 price target on the stock, up previously from $25.00.
9/16
08:03 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
High
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
9/16
08:02 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $16.00 price target on the stock.
High
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $16.00 price target on the stock.
9/14
03:10 am
acrv
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
Medium
Report
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
9/10
08:00 am
acrv
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
Medium
Report
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
9/9
07:00 am
acrv
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
Low
Report
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
9/6
10:12 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at Piper Sandler Companies. They now have a $30.00 price target on the stock.
Low
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at Piper Sandler Companies. They now have a $30.00 price target on the stock.
9/5
08:53 am
acrv
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely [Yahoo! Finance]